KalVista Pharmaceuticals up after EU, Swiss approval for swelling disorder drug

Kalvista Pharmaceuticals

19/09/2025 12:22

** Shares of KalVista Pharmaceuticals KALV.O up 2% at $14.15 premarket

** Company says European Commission and Swiss regulator, Swissmedic, have approved its drug Ekterly, the first on-demand oral treatment for a type of hereditary swelling disorder in adults and adolescents aged 12 years and older

** Hereditary angioedema is a life-threatening condition that causes sudden, dangerous swelling in the body, including the skin, digestive tract and upper respiratory system, due to deficiency in a protein known as C1 inhibitor

** Company expects to initiate its first European launch in Germany in Q4 2025, with availability in Switzerland anticipated in H2 2026, pending finalization of reimbursement plans

** As of last close, stock up 63.8% YTD

 (Reporting by Siddhi Mahatole in Bengaluru)

 ((siddhi.mahatole@thomsonreuters.com))